Verastem, Inc. Stock
Verastem, Inc. Stock price
Key metrics
| Market capitalization | $426.96m |
| Enterprise Value | $384.90m |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | negative |
| Free Cash Flow (TTM) Free Cash Flow | $-115.15m |
| Cash position | $117.57m |
| P/E forward | negative |
| P/S forward | 19.01 |
| EV/Sales forward | 17.14 |
Is Verastem, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
Verastem, Inc. Stock Analysis
Analyst Opinions
9 Analysts have issued a Verastem, Inc. forecast:
Analyst Opinions
9 Analysts have issued a Verastem, Inc. forecast:
Financial data from Verastem, Inc.
| Dec '24 |
+/-
%
|
||
| Revenue | 10 10 |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -87 -87 |
6%
6%
|
EBIT (Operating Income) EBIT | -87 -87 |
6%
6%
|
| Net Profit | -97 -97 |
11%
11%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Verastem, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Verastem, Inc. Stock News
Company Profile
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
| Head office | United States |
| CEO | Dan Paterson |
| Employees | 78 |
| Founded | 2010 |
| Website | www.verastem.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
